Shanta Chawla

Belinostat in Patients With Relapsed or Refractory Peripheral T-Cell Lymphoma: Results of the Pivotal Phase II BELIEF (CLN-19) Study

Owen A. O’Connor, Steven M. Horwitz, Tamás Masszi et al. · Journal of Clinical Oncology · 2015 · 547 citations · Full text

Medicine, Oncology, Pharmacotherapy +15

A Phase <scp>II</scp> trial of Belinostat ( <scp>PXD</scp> 101) in patients with relapsed or refractory peripheral or cutaneous T‐cell lymphoma

Francine M. Foss, Ranjana H. Advani, Madeleine Duvic et al. · British Journal of Haematology · 2014 · 190 citations · Full text

Medicine, Oncology, Pharmacology +16

Belinostat, a novel pan-histone deacetylase inhibitor (HDACi), in relapsed or refractory peripheral T-cell lymphoma (R/R PTCL): Results from the BELIEF trial.

Owen A. O’Connor, Tamás Masszi, Kerry J. Savage et al. · Journal of Clinical Oncology · 2013 · 58 citations

Medicine, Hematology, Pharmacology +10

Phase I/II Pilot Study of Intravesical Apaziquone (EO9) for Superficial Bladder Cancer

Rajiv Puri, Victor Palit, Paul M. Loadman et al. · The Journal of Urology · 2006 · 45 citations

Medicine, Oncology, Urology +7

Eflapegrastim, a Long-Acting Granulocyte-Colony Stimulating Factor for the Management of Chemotherapy-Induced Neutropenia: Results of a Phase III Trial

Lee S. Schwartzberg, Gajanan Bhat, Julio A. Peguero et al. · The Oncologist · 2020 · 30 citations · Full text

Medicine, Oncology, Pharmacology +17